Cargando…
Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study
BACKGROUND: An open-label, non-comparative study assessed the efficacy and safety of nivolumab in Japanese patients with first recurrence glioblastoma. METHODS: Patients with first recurrence of histologically confirmed World Health Organization Grade IV glioma, after treatment with temozolomide and...
Autores principales: | Aoki, Tomokazu, Kagawa, Naoki, Sugiyama, Kazuhiko, Wakabayashi, Toshihiko, Arakawa, Yoshiki, Yamaguchi, Shigeru, Tanaka, Shota, Ishikawa, Eiichi, Muragaki, Yoshihiro, Nagane, Motoo, Nakada, Mitsutoshi, Suehiro, Satoshi, Hata, Nobuhiro, Kuroda, Junichiro, Narita, Yoshitaka, Sonoda, Yukihiko, Iwadate, Yasuo, Natsumeda, Manabu, Nakazato, Yoichi, Minami, Hironobu, Hirata, Yuki, Hagihara, Shunsuke, Nishikawa, Ryo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580927/ https://www.ncbi.nlm.nih.gov/pubmed/34586548 http://dx.doi.org/10.1007/s10147-021-02028-1 |
Ejemplares similares
-
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)
por: Nagane, Motoo, et al.
Publicado: (2012) -
Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies
por: Ohno, Makoto, et al.
Publicado: (2022) -
Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013) -
COT-28 Questionnaire Survey Regarding Working Condition of the Members Belongs to the Japan Society for Neuro-Oncology (JSNO) by the Gender Equality and Diversity Committee of the JSNO, 2021
por: Fujiamaki, Takamitsu, et al.
Publicado: (2021) -
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial
por: Narita, Yoshitaka, et al.
Publicado: (2021)